Zhejiang Hisoar Pharmaceutical Co., Ltd. (SZSE:002099) released audited financial results for 2007 on April 21 in the company's annual report.
According to the report, the company's 2007 revenue was RMB 1.03 billion, up 23.56% year-over-year; net income dropped 50.74% to RMB 23.37 million, and EPS was RMB 0.19, decreasing of 54.76% compared with the same period of 2006.
Zhejiang Hisoar Pharmaceutical Co., Ltd (Hisoar) is principally engaged in the production and sale of drug substance and bulk drug intermediates. Headquartered in Taizhou, Zhejiang Province, the People's Republic of China, the Company offers antibiotics, anti-diabetes drugs, antivirus drugs, anthelmintic drugs and melbinum, among others. The Company distributes its products within the domestic market and to overseas markets. As of December 31, 2006, the Company had one major subsidiary and one major associate.
